Sodium-dependent dopamine transporter · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Sodium-dependent dopamine transporter shows approved-linked disease relevance led by attention deficit hyperactivity disorder. 5 more disease programs remain visible in the same review block. 13 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q01959. Start with attention deficit hyperactivity disorder, then reuse UniProt Q01959 as the stable protein anchor across project notes and exports.
Start with attention deficit hyperactivity disorder, then reuse UniProt Q01959 as the stable protein anchor across project notes and exports.
Sodium-dependent dopamine transporter shows approved-linked disease relevance led by attention deficit hyperactivity disorder. 5 more disease programs remain visible in the same review block. 13 linked drugs remain visible in the same block.
Start review with attention deficit hyperactivity disorder because it currently carries approved-linked support. Linked drugs include AMPHETAMINE, AMPHETAMINE ASPARTATE, AMPHETAMINE SULFATE, ARMODAFINIL. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxySodium-dependent dopamine transporter
Review this target as Sodium-dependent dopamine transporter, mapped to UniProt Q01959. Sequence length is 620 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Sodium-dependent dopamine transporter as ChEMBL target CHEMBL238, mapped to UniProt Q01959. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Sodium-dependent dopamine transporter is the right protein anchor across sources, using UniProt Q01959 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why attention deficit hyperactivity disorder is currently framed as approved-linked support. It currently carries 13 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Sodium-dependent dopamine transporter |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | Q01959 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Sodium-dependent dopamine transporter |
| UniProt Accession | Q01959 |
| Component Type | Protein |
| Sequence Length | 620 aa |
Sodium-dependent dopamine transporter
Review this target as Sodium-dependent dopamine transporter, mapped to UniProt Q01959. Sequence length is 620 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Sodium-dependent dopamine transporter shows approved-linked disease relevance led by attention deficit hyperactivity disorder. 5 more disease programs remain visible in the same review block.
Start review with attention deficit hyperactivity disorder because it currently carries approved-linked support. Linked drugs include AMPHETAMINE, AMPHETAMINE ASPARTATE, AMPHETAMINE SULFATE, ARMODAFINIL. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL353333 | 9.92 | Ki | 0.12 | Preclinical |
| CHEMBL1818444 | 9.8 | Ki | 0.1585 | Preclinical |
| CHEMBL42553 | 9.7 | Ki | 0.2 | Preclinical |
| CHEMBL1818445 | 9.7 | Ki | 0.1995 | Preclinical |
| CHEMBL28394 | 9.66 | Ki | 0.22 | Preclinical |
| CHEMBL495464 | 9.64 | IC50 | 0.23 | Preclinical |
| CHEMBL422290 | 9.64 | IC50 | 0.227 | Preclinical |
| CHEMBL91184 | 9.52 | IC50 | 0.3 | Preclinical |
| CHEMBL494626 | 9.49 | IC50 | 0.32 | Preclinical |
| CHEMBL28394 | 9.44 | IC50 | 0.36 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 520 | 960 | 6.9 |
| cell-based format | 332 | 2,075 | 6.5 |
| assay format | 19 | 197 | 7.2 |
| tissue-based format | 15 | 110 | 7.3 |
| cell membrane format | 11 | 169 | 6.4 |
| cell-free format | 1 | 1 | 5.1 |
| subcellular format | 1 | 49 | 7.3 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 15 | 13 | 6.3 |
| single protein format | 9 | 20 | 6.6 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 10 | 15 | 7.4 |
| cell-based format | 9 | 99 | 6.8 |
| tissue-based format | 4 | 9 | 7.3 |
| cell membrane format | 1 | 2 | 7.9 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 1 | 1 | 4.7 |